cellceutix, Inc. (CTIX)

Oncology Corporate Profile

Stock Performance

1.8000
-0.0200

HQ Location

100 Cumming Center, Suite 151-B
Beverly, MA 1915

Company Description

cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antimicrobial applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations.

Website: http://cellceutix.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
kevetrinimmunotherapyOvarian cancerI

View additional information on product candidates here »

Source: http://cellceutix.com/

Recent News Headlines

5/27/2017 06:17 am

5/27/2017 06:17 am

5/27/2017 06:17 am

5/27/2017 06:17 am

5/23/2017 12:17 pm

5/18/2017 06:17 am

5/18/2017 06:17 am

5/18/2017 06:17 am

5/11/2017 06:17 am

5/10/2017 06:17 am

5/10/2017 06:17 am

5/10/2017 06:17 am

4/19/2017 12:17 pm

4/19/2017 12:17 pm

4/19/2017 12:17 pm

4/19/2017 12:17 pm

4/17/2017 06:17 am

4/10/2017 06:17 am

Cellceutix Reports Very Encouraging Interim Analysis of Phase 2 Drug Candidate Brilacidin for Severe Oral Mucositis (OM) in Head and Neck Cancer Patients; High Potential for Preventative Treatment

3/27/2017 02:00 pm

[GlobeNewswire] - BEVERLY, Mass., March 27, 2017-- Cellceutix Corporation,, today presented positive results from the Company's ongoing randomized, double-blind Phase 2 study of Brilacidin in the prevention and control ...

Cellceutix Releases Favorable Topline Findings as Part of Interim Analysis of Phase 2 Drug Candidate Brilacidin for the Treatment of Inflammatory Bowel Disease

3/21/2017 11:03 am

[GlobeNewswire] - BEVERLY, Mass., March 21, 2017-- Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, ...